{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:52:12Z","timestamp":1789624332135,"version":"build-2803163510"},"reference-count":121,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Obesity and nonalcoholic fatty liver disease (NAFLD) are common worldwide health problems with a strong relationship in between. NAFLD is currently the most common cause of abnormal liver function tests (LFT) because of obesity pandemic. The question is NAFLD the only player of abnormal LFT in obesity?<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methodology:<\/jats:title>\n            <jats:p>This article reviews the most important topics regarding the derangements of LFT in obesity through a PubMed search strategy for all English-language literature.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The reported abnormal LFT in obesity were increased serum levels of transaminases (alanine aminotransaminase, aspartate aminotransaminase), gamma glutamyl transferase, and alkaline phosphatase and decreased serum levels of bilirubin and albumin. Besides novel potential hepatic markers of NAFLD\/NASH such as triglycerides\/high-density lipoprotein cholesterol ratio, sex hormone\u2013binding globulin, fibroblast growth factor 21, and markers of hepatocyte apoptosis i.e. cytokeratin 18 and microribonucleic acids (miRNAs). Beyond NAFLD, there are other underlying players for the abnormal LFT in obesity such as oxidative stress, inflammation, and insulin resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Derangements of LFT in obesity are attributed to NAFLD but also to obesity itself and its related oxidative stress, insulin resistance, and chronic inflammatory state. Abnormal LFT predict more than just liver disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/j.pbj.0000000000000228","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T15:13:48Z","timestamp":1697555628000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Impact of obesity on liver function tests: is nonalcoholic fatty liver disease the only player? A review article"],"prefix":"10.1097","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-2054","authenticated-orcid":false,"given":"Mervat M.","family":"El-Eshmawy","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mansoura Specialized Medical Hospital, Faculty of Medicine, Mansoura University, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"R2-20241001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease- meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R3-20241001","first-page":"62","article-title":"Non-alcoholic fatty liver disease (NAFLD) in obesity","volume":"8","author":"Patell","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"R4-20241001","first-page":"379","article-title":"Approach to the patient with abnormal liver tests","volume":"2","author":"Mahl","year":"1998","journal-title":"Lippincotts Prim Care Pract"},{"key":"R5-20241001","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.2174\/13816128113199990381","article-title":"Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"Curr Pharm Des."},{"key":"R6-20241001","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"R7-20241001","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2214\/AJR.16.16565","article-title":"Accuracy of liver fat quantification with advanced CT, MRI, and ultrasound techniques: prospective comparison with MR spectroscopy","volume":"208","author":"Kramer","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"R8-20241001","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"R9-20241001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"R10-20241001","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig Dis Sci"},{"key":"R11-20241001","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastro Hepat"},{"key":"R12-20241001","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"R13-20241001","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"R14-20241001","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"R15-20241001","doi-asserted-by":"crossref","first-page":"592404","DOI":"10.5402\/2011\/592404","article-title":"Obesity, Visceral Fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease","volume":"2011","author":"Mirza","year":"2011","journal-title":"ISRN Gastroenterol"},{"key":"R16-20241001","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1572-0241.2005.00341.x","article-title":"The prevalence of predictors of elevated serum aminotransferase activity in the United States in 1999-2002","volume":"101","author":"Ioannou","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R17-20241001","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1381\/096089202320995592","article-title":"Liver damage in obese patients","volume":"12","author":"Del Gaudio","year":"2002","journal-title":"Obes Surg"},{"key":"R20-20241001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ajcp\/104.1.23","article-title":"Regression of hepatic fibrosis in morbidly obese persons after gastric bypass","volume":"104","author":"Silverman","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"R21-20241001","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1572-0241.1999.01006.x","article-title":"The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease","volume":"94","author":"Sorbi","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R22-20241001","first-page":"290","article-title":"Prevalence of hepatic steatosis and its relation to liver function tests and lipid profile in patients at medical check-up","volume":"84","author":"Brise\u00f1o-Bass","year":"2019","journal-title":"Rev Gastroenterol Mex"},{"key":"R23-20241001","doi-asserted-by":"crossref","first-page":"dgz010","DOI":"10.1210\/clinem\/dgz010","article-title":"The effect of overweight and obesity on liver biochemical markers in children and adolescents","volume":"105","author":"Johansen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20241001","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"R25-20241001","first-page":"1349","article-title":"Liver pathology in morbidly obese patients with and without diabetes","volume":"85","author":"Silverman","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"R26-20241001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/10641963.2017.1281940","article-title":"A comparative research on obesity hypertension by the comparisons and associations between waist circumference, body mass index with systolic and diastolic blood pressure, and the clinical laboratory data between four special Chinese adult groups","volume":"40","author":"Wu","year":"2018","journal-title":"Clin Exp Hypertens"},{"key":"R27-20241001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12872-015-0060-y","article-title":"Association between elevated serum alanine aminotransferase and cardiometabolic risk factors in rural Chinese population: a cross-sectional study","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"R28-20241001","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/oby.22669","article-title":"Obesity predicts liver function testing and abnormal liver results","volume":"28","author":"Li","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"R29-20241001","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jsams.2017.04.006","article-title":"Cardiorespiratory fitness, waist circumference and liver enzyme levels in European adolescents; the HELENA cross-sectional study","volume":"20","author":"Medrano","year":"2017","journal-title":"J Sci Med Sport"},{"key":"R30-20241001","first-page":"38","article-title":"The prevalence of liver and gallbladder pathologies in overweight and obese patients","volume":"90","author":"Popova","year":"2012","journal-title":"Klin Med (Mosk)"},{"key":"R31-20241001","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1381\/0960892053268273","article-title":"Gallbladder pathology in morbid obesity","volume":"15","author":"Dittrick","year":"2005","journal-title":"Obes Surg"},{"key":"R32-20241001","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1172\/JCI108180","article-title":"Effect of obesity and caloric intake on biliary lipid metabolism in man","volume":"56","author":"Bennion","year":"1975","journal-title":"J Clin Invest"},{"key":"R33-20241001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/BF01536623","article-title":"Gallbladder kinetics in obese patients. Effect of a regular meal and low-calorie meal","volume":"33","author":"Marzio","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R34-20241001","first-page":"626","article-title":"Alkaline phosphatase: can it be considered as an indicator of liver fibrosis in non-alcoholic steatohepatitis with type 2 diabetes?","volume":"112","author":"Kocabay","year":"2011","journal-title":"Bratisl Lek Listy"},{"key":"R35-20241001","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s11695-011-0525-8","article-title":"Effects of laparoscopic Roux-en-Y gastic bypass (LRYGP) on weight loss and biomarker parameters in morbidly obese patients: a 12-month follow-up","volume":"21","author":"Toolabi","year":"2011","journal-title":"Obes Surg"},{"key":"R36-20241001","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1507\/endocrj.EJ12-0331","article-title":"Serum alkaline phosphatase, body composition, and risk of metabolic syndrome in middle-aged Korean","volume":"60","author":"Kim","year":"2013","journal-title":"Endocr J"},{"key":"R37-20241001","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ab.2006.04.028","article-title":"The relationship between alkaline phosphatase activity and intracellular lipid accumulation in murine 3T3-L1 cells and human preadipocytes","volume":"354","author":"Ali","year":"2006","journal-title":"Anal Biochem"},{"key":"R38-20241001","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.bbagen.2015.09.014","article-title":"Tissue alkaline phosphatase is involved in lipid metabolism and gene expression and secretion of adipokines in adipocytes","volume":"1850","author":"Hern\u00e1ndez-Mosqueira","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"R39-20241001","first-page":"797","article-title":"Elevated serum liver enzymes in obesity: a dilemma during clinical trials","volume":"15","author":"Golik","year":"1991","journal-title":"Int J Obes"},{"key":"R40-20241001","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/ATVBAHA.112.300826","article-title":"Alkaline pohsphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men","volume":"33","author":"Wannamethee","year":"2013","journal-title":"Areterioscler Thromb Vasc Biol"},{"key":"R41-20241001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0003-9861(84)90356-4","article-title":"Can biological calcification occur in the presence of pyrophosphate?","volume":"231","author":"Meyer","year":"1984","journal-title":"Arch Biochem Biophys"},{"key":"R42-20241001","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1053\/gast.2002.36061","article-title":"AGA technical review on the evaluation of liver chemistry tests","volume":"123","author":"Green","year":"2002","journal-title":"Gastroenterology"},{"key":"R43-20241001","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1381\/096089206778663805","article-title":"Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement","volume":"16","author":"Dixon","year":"2006","journal-title":"Obes Surg"},{"key":"R44-20241001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1665-2681(19)31790-9","article-title":"Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis","volume":"8","author":"Mu\u00f1oz","year":"2009","journal-title":"Ann Hepatol"},{"key":"R45-20241001","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"R46-20241001","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.diabres.2007.06.014","article-title":"Hepatic fat content-independent association of the serum level of gamma-glutamyl transferase with visceral adiposity, but not subcutaneous adiposity","volume":"79","author":"Iwasaki","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"R47-20241001","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5551\/jat.14415","article-title":"Comparison of the impact of changes in waist circumference and body mass index in relation to changes in serum gamma-glutamyl transferase levels","volume":"20","author":"Sakamoto","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"R48-20241001","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5455\/medarh.2017.72.112-115","article-title":"Serum gamma-glutamyl transferase and obesity: is there a link?","volume":"72","author":"Coku","year":"2018","journal-title":"Med Arch"},{"key":"R49-20241001","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10715760410001694026","article-title":"Is serum gamma glutamyl transferase a marker of oxidative stress?","volume":"38","author":"Lee","year":"2004","journal-title":"Free Radic Res"},{"key":"R50-20241001","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2337\/db10-1806","article-title":"Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women","volume":"60","author":"Bonnet","year":"2011","journal-title":"Diabetes"},{"key":"R51-20241001","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.atherosclerosis.2005.11.036","article-title":"Elevated serum levels of alanine aminotransferase and gamma glutamyl transferase are markers of inflammation and oxidative stress independent of the metabolic syndrome","volume":"189","author":"Yamada","year":"2006","journal-title":"Atherosclerosis"},{"key":"R52-20241001","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1161\/ATVBAHA.108.170597","article-title":"Longitudinal change in serum gamma-glutamyl transferase and cardio vascular disease mortality: a prospective population-based study in 76,113 Austrian adults","volume":"28","author":"Strasak","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R53-20241001","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1478-3231.2008.01716.x","article-title":"Bilirubin in clinical practice: a review","volume":"28","author":"Fevery","year":"2008","journal-title":"Liver Int"},{"key":"R55-20241001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fphar.2012.00055","article-title":"The role of bilirubin in diabetes, metabolic syndrome, and cardio-vascular diseases","volume":"3","author":"Vitek","year":"2012","journal-title":"Front Pharmacol"},{"key":"R56-20241001","first-page":"841","article-title":"Antioxidant activities of bile pigments","volume":"6","author":"Stocker","year":"2004","journal-title":"Antioxid Redox Signal"},{"key":"R57-20241001","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.3029864","article-title":"Bilirubin is an antioxidant of possible physiological importance","volume":"235","author":"Stocker","year":"1987","journal-title":"Science"},{"key":"R58-20241001","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.metabol.2013.01.011","article-title":"Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults: an early indicator of metabolic syndrome?","volume":"62","author":"Jenko-Pra\u017enikar","year":"2013","journal-title":"Metabolism"},{"key":"R59-20241001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1871530321999210128201259","article-title":"Association between total bilirubin levels and cardio-metabolic risk factors related to obesity","volume":"22","author":"El-Eshmawy","year":"2022","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R60-20241001","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1463-1326.2007.00692.x","article-title":"Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity","volume":"9","author":"Vincent","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"R61-20241001","doi-asserted-by":"crossref","first-page":"58","DOI":"10.21037\/jxym.2017.07.05","article-title":"Does serum bilirubin prevent cardiovascular disease?","volume":"2","author":"Oda","year":"2017","journal-title":"J Xiangya Med"},{"key":"R62-20241001","doi-asserted-by":"crossref","first-page":"e0153427","DOI":"10.1371\/journal.pone.0153427","article-title":"Bilirubin binding to PPAR alpha inhibits lipid accumulation","volume":"11","author":"Stec","year":"2016","journal-title":"PLoS One"},{"key":"R63-20241001","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1096\/fj.04-2368fje","article-title":"Bilirubin decreases nos 2 expression via inhibition of NAD (P) H oxidase: implications for protection against endotoxic shock in rats","volume":"19","author":"Lanone","year":"2005","journal-title":"FASEB J"},{"key":"R64-20241001","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/ATVBAHA.116.308749","article-title":"Adipocyte-specific deficiency of NADPH oxidase 4 delays the onset of insulin resistance and attenuates adipose tissue inflammation in obesity","volume":"37","author":"Den Hartigh","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R65-20241001","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1210\/en.2013-1667","article-title":"Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation","volume":"155","author":"Dong","year":"2014","journal-title":"Endocrinology"},{"key":"R66-20241001","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3350\/cmh.2012.18.4.383","article-title":"Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease","volume":"18","author":"Kwak","year":"2012","journal-title":"Clin Mol Hepatol"},{"key":"R67-20241001","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mehy.2016.08.013","article-title":"Does bilirubin prevent hepatic steatosis through activation of the PPAR\u03b1 nuclear receptor?","volume":"95","author":"Hinds","year":"2016","journal-title":"Med Hypotheses"},{"key":"R68-20241001","doi-asserted-by":"crossref","first-page":"594574","DOI":"10.3389\/fphar.2020.594574","article-title":"Bilirubin nanoparticles reduce diet-induced hepatic steatosis, improve fat utilization, and increase plasma \u03b2-hydroxybutyrate","volume":"11","author":"Hinds","year":"2020","journal-title":"Front Pharmacol"},{"key":"R69-20241001","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.etap.2013.08.015","article-title":"Models of hepatotoxicity and the underlying cellular, biochemical and immunological mechanism(s): a critical discussion","volume":"37","author":"Ingawale","year":"2014","journal-title":"Environ Toxicol Pharmacol"},{"key":"R70-20241001","first-page":"13","article-title":"Tests of liver function in obese school children","volume":"56","author":"Angulo","year":"2015","journal-title":"Invest Clin"},{"key":"R71-20241001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clinbiochem.2017.10.010","article-title":"Pre-operative and post-operative changes in CRP and other biomarkers sensitive to inflammatory status in patients with severe obesity undergoing laparoscopic sleeve gastrectomy","volume":"52","author":"Randell","year":"2018","journal-title":"Clin Biochem"},{"key":"R72-20241001","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrneph.2016.75","article-title":"Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis","volume":"12","author":"D'Agati","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R73-20241001","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s11695-015-1869-2","article-title":"A 7-year clinical audit of 1107 cases comparing sleeve gastrectomy, Roux-En-Y gastric bypass, and minigastric bypass, to determine an effective and safe bariatric and metabolic procedure","volume":"26","author":"Jammu","year":"2016","journal-title":"Obes Surg"},{"key":"R74-20241001","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3949\/ccjm.71.8.657","article-title":"Nonalcoholic fatty liver disease and the epidemic of obesity","volume":"71","author":"Collantes","year":"2004","journal-title":"Cleve Clin J Med"},{"key":"R75-20241001","doi-asserted-by":"crossref","first-page":"e94059","DOI":"10.1371\/journal.pone.0094059","article-title":"Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance","volume":"9","author":"Kahl","year":"2014","journal-title":"PLoS One"},{"key":"R76-20241001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"R77-20241001","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"R78-20241001","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.24356","article-title":"Fatty liver index and mortality: the Cremona study in the 15th year of follow-up","volume":"54","author":"Calori","year":"2011","journal-title":"Hepatolog"},{"key":"R79-20241001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jgh.13814","article-title":"Fatty liver index and hepatic steatosis index predict non-alcoholic fatty liver disease in type 1 diabetes","volume":"33","author":"Svikl\u0101ne","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"R80-20241001","doi-asserted-by":"crossref","first-page":"e000904","DOI":"10.1136\/bmjdrc-2019-000904","article-title":"Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications","volume":"8","author":"Ciardullo","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"R81-20241001","doi-asserted-by":"crossref","first-page":"647459","DOI":"10.3389\/fendo.2021.647459","article-title":"Long working hours and risk of nonalcoholic fatty liver disease: Korea National Health and Nutrition Examination Survey VII","volume":"12","author":"Song","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R82-20241001","first-page":"1682","article-title":"Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis","volume":"103","author":"Wong","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R83-20241001","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"R84-20241001","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"R85-20241001","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"R86-20241001","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study","volume":"357","author":"Imbert-Bismut","year":"2001","journal-title":"Lancet"},{"key":"R87-20241001","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/apt.13770","article-title":"Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference","volume":"44","author":"Munteanu","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R88-20241001","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/jgh.13671","article-title":"Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with nonalcoholic fatty liver disease","volume":"32","author":"Loong","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"R89-20241001","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12944-016-0270-z","article-title":"The triglyceride to high-density lipoprotein cholesterol (TG\/HDL-C) ratio as a predictor of insulin resistance but not of beta cell function in a Chinese population with different glucose tolerance status","volume":"15","author":"Zhou","year":"2016","journal-title":"Lipids Health Dis"},{"key":"R90-20241001","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12944-019-0986-7","article-title":"Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross sectional study","volume":"18","author":"Fan","year":"2019","journal-title":"Lipids Health Dis"},{"key":"R91-20241001","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-021-01561-2","article-title":"The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease","volume":"20","author":"Sheng","year":"2021","journal-title":"Lipids Health Dis"},{"key":"R92-20241001","first-page":"167","article-title":"Overproduction of altered VLDL in an insulin-resistance rat model: influence of SREBP-1c and PPAR-alpha","volume":"27","author":"Lucero","year":"2015","journal-title":"Clin Investig Arterioscler"},{"key":"R93-20241001","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.tem.2011.04.007","article-title":"Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance","volume":"22","author":"Choi","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"R94-20241001","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/obr.12064","article-title":"Adiponectin and lipoprotein metabolism","volume":"14","author":"Christou","year":"2013","journal-title":"Obes Rev"},{"key":"R95-20241001","first-page":"211","article-title":"Sex hormone binding globulin (SHBG) as a marker of clinical disorders","volume":"40","author":"Golds\u030ctajn","year":"2016","journal-title":"Coll Antropol"},{"key":"R96-20241001","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/er.2018-00158","article-title":"Reproductive endocrinology of nonalcoholic fatty liver disease","volume":"40","author":"Grossmann","year":"2019","journal-title":"Endocr Rev"},{"key":"R97-20241001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fendo.2021.641446","article-title":"SHBG as a marker of NAFLD and metabolic impairments in women referred for oligomenorrhea and\/or hirsutism and in women with sexual dysfunction","volume":"12","author":"Di Stasi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R98-20241001","doi-asserted-by":"crossref","first-page":"dgz244","DOI":"10.1210\/clinem\/dgz244","article-title":"Serum SHBG is associated with the development and regression of nonalcoholic fatty liver disease: a prospective study","volume":"105","author":"Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R99-20241001","first-page":"545","article-title":"Sex hormone-binding globulin reduction in metabolic disorders may play a role in NAFLD development","volume":"158","author":"Saez-Lopez","year":"2017","journal-title":"Endocrinology"},{"key":"R100-20241001","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cen.12095","article-title":"Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives","volume":"78","author":"Woo","year":"2013","journal-title":"Clin Endocrinol"},{"key":"R101-20241001","doi-asserted-by":"crossref","first-page":"9729107","DOI":"10.1155\/2017\/9729107","article-title":"Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta- analysis","volume":"2017","author":"He","year":"2017","journal-title":"Biomed Res Int"},{"issue":"3","key":"R102-20241001","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.metabol.2014.11.009","article-title":"The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy","volume":"64","author":"Liu","year":"2015","journal-title":"Metabolism"},{"key":"R103-20241001","doi-asserted-by":"crossref","first-page":"iii-v","DOI":"10.1016\/j.metabol.2019.01.005","article-title":"Fibroblast growth factor 21: a role in cardiometabolic disorders and cardiovascular risk prediction?","volume":"93","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"issue":"10165","key":"R104-20241001","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"R105-20241001","doi-asserted-by":"crossref","first-page":"155329","DOI":"10.1016\/j.metabol.2022.155329","article-title":"Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH","volume":"137","author":"Larsson","year":"2022","journal-title":"Metabolism"},{"key":"R106-20241001","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2013.12.026","article-title":"Biomarkers of liver cell death","volume":"60","author":"Eguchi","year":"2014","journal-title":"J Hepatol"},{"key":"R107-20241001","doi-asserted-by":"crossref","first-page":"113664","DOI":"10.1016\/j.bcp.2019.113664","article-title":"Clinical prospects of biomarkers for the early detection and\/or prediction of organ injury associated with pharmacotherapy","volume":"170","author":"Tajima","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"R108-20241001","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.cgh.2014.05.010","article-title":"Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease","volume":"12","author":"Vuppalanchi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R109-20241001","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease- the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"Kwok","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R110-20241001","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2010.08.023","article-title":"An apoptosis panel for nonalcoholic steatohepatitis diagnosis","volume":"54","author":"Tamimi","year":"2011","journal-title":"J Hepatol"},{"key":"R111-20241001","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/MEG.0000000000002176","article-title":"Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"33","author":"Tada","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R112-20241001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.28776","article-title":"Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease","volume":"65","author":"Ajmera","year":"2017","journal-title":"Hepatology"},{"key":"R113-20241001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.24706","article-title":"Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease","volume":"55","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"R114-20241001","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jgh.13235","article-title":"The development of a non- invasive model to predict the presence of non- alcoholic steatohepatitis in patients with non- alcoholic fatty liver disease","volume":"31","author":"Goh","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"R115-20241001","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R116-20241001","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/j.orcp.2013.05.004","article-title":"Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer","volume":"7","author":"Matsuda","year":"2013","journal-title":"Obes Res Clin Pract"},{"key":"R117-20241001","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2013.08.037","article-title":"Gender\u2010specific correlation between plasma myeloperoxidase levels and serum high\u2010density lipoprotein\u2010associated paraoxonase\u20101 levels in patients with stable and unstable coronary artery disease","volume":"231","author":"Yunoki","year":"2013","journal-title":"Atherosclerosis"},{"key":"R118-20241001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/oby.22354","article-title":"Oxidized HDL, adipokines, and endothelial dysfunction: a potential biomarker profile for cardiovascular risk in women with obesity","volume":"7","author":"Peterson","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"R119-20241001","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1440-1746.1997.tb00450.x","article-title":"Review: nonalcoholic steatohepatitis","volume":"12","author":"Ludwig","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"R120-20241001","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3945\/jn.112.165563","article-title":"Opuntia ficus indica (nopal) attenuates hepatic steatosis and oxidative stress in obese Zucker (fa\/fa) rats","volume":"142","author":"Mor\u00e1n-Ramos","year":"2012","journal-title":"J Nutr"},{"key":"R121-20241001","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lfs.2012.11.004","article-title":"Nonalcoholic fatty liver disease: current and potential therapies","volume":"92","author":"Ibrahim","year":"2013","journal-title":"Life Sci"},{"key":"R122-20241001","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2010.06.021","article-title":"Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C","volume":"54","author":"Garc\u00eda-Monz\u00f3n","year":"2011","journal-title":"J Hepatol"},{"key":"R123-20241001","first-page":"5172","article-title":"Mediation of inflammation, obesity and fatty liver disease by advanced glycation endoproducts","volume":"21","author":"Xiong","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R124-20241001","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"key":"R125-20241001","doi-asserted-by":"crossref","first-page":"e000096","DOI":"10.1136\/bmjgast-2016-000096","article-title":"Circulating miRNA in patients with nonalcoholic fatty liver disease and coronary artery disease","volume":"3","author":"Mehta","year":"2016","journal-title":"BMJ Open Gastroenterol"}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T19:02:27Z","timestamp":1727809347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":121,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/j.pbj.0000000000000228","relation":{},"ISSN":["2444-8664"],"issn-type":[{"value":"2444-8664","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2023-01-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}